Pivotal announces the issuance of two patents both related to the combination of VASCAZEN® with key Cholesterol Lowering Agents (Statins) and Cholesterol Absorption Inhibitors

WOODBRIDGE, ON, Feb. 10, 2015 /CNW/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that the U.S. Patent and Trademark Office (USPTO) has issued Patent Number 8,951,514 titled "STATIN and Omega-3 Fatty Acids for Reduction of Apolipoprotein-B Levels" and Patent Number 8,952,000 titled "Cholesterol Absorption Inhibitor and Omega-3 Fatty Acids for the Reduction of Cholesterol and for the Prevention or Reduction of Cardiovascular, Cardiac and Vascular Events." Both of these patents cover VASCAZEN®'s formulation in conjunction with a Statin and Cholesterol Absorption Inhibitor respectively. These patents have terms that expire no earlier than 2032.

"The issuance of these patents is an important milestone for the Company as it protects our formulation in conjunction with Statins and Cholesterol Absorption Inhibitors," said Dr. George Jackowski, Pivotal's founder and Chief Scientific Officer. " We believe these combinations could significantly benefit the management of cardiovascular patients going forward beyond normalizing their lipid profile."

These issued patents are part of Pivotal's expanding patent portfolio that protects its unique formulation. The Company has a total of three issued patents and five (5) patent applications currently in prosecution in the U.S. The Company is pursuing patent applications related to VASCAZEN®'s formulation, composition and combinations with existing cardiovascular drugs in the U.S. and in multiple jurisdictions outside the United States.

About VASCAZEN®

VASCAZEN® is currently available in the U.S. as a prescription-only medical food specifically formulated for the dietary management of an Omega-3 deficiency in cardiovascular patients. VASCAZEN® is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by a series of both U.S. and foreign patents.

VASCAZEN® has been clinically shown to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase of HDL without negative impact on the LDL-C lipid profile.

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (OTCQX:PVTTF; CSE:PVO), specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics' lead product VASCAZEN® is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications.  OMAZEN® is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. OMAZEN® is a patented product available for sale and distribution in Canada. BeneFishial™ is the first product in Pivotal's new nutraceutical product line, which has been specifically designed to be sold in the OTC direct to retail or direct to consumer markets.

Disclosure Notice

The information contained in this document is as February 10, 2015. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSE listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this information.

SOURCE Pivotal Therapeutics Inc.

For further information: Company Contacts: Kristine DiMatteo, Communications and Public Relations Manager, Phone: 905-856-9797 ext. 231, E-Mail: kdimatteo@pivotaltherapeutics.us

RELATED LINKS
www.pivotaltherapeutics.us

Organization Profile

Pivotal Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890